Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Natalia Levitskaya

Citation

Annals of Oncology (2018) 29 (suppl_8): viii1-viii13. 10.1093/annonc/mdy268

Authors

N. Levitskaya1, O. Vostriukhina2, I. Poddubnaia1

Author affiliations

  • 1 Oncology, Russian Medical Academy of Continuous Vocational Training, 123242 - Moscow/RU
  • 2 Molecular And Radiation Biophysics, Petersburg nuclear physics institute named by B.P.Konstantinov, 188300 - Russia, Leningradskaya Oblast, Gatchina, , mkr. Orlova roshcha./RU
More

Resources

Abstract 5169

Background

Uterine carcinosarcoma is a malignant mixed Mullerian tumour, composed of epithelial and stromal components. Most uterine carcinosarcomas are monoclonal tumours, but a small proportion of them is a collision of carcinoma and sarcoma.

Methods

This research is based on the investigation of formalin‐fixed, paraffin‐embedded tissue blocks from 13 women undergoing primary surgical treatment between 1961–2010, that were retrieved from the archival collections of the pathoanatomical department of the Institute of Oncology named after N.N. Petrov. Mutations of TP53, PTEN and K-RAS genes were analyzed to determine clonality of uterine carcinosarcoma. DNAs were extracted by proteinase K digestion («Fisher» US) by the method of Herrington, C.S. & McGee, J.O. Mutations of TP53, PTEN and K-RAS were defined by single-strand conformation polymorphism with the next sequence. The found mutations in the TP53 (exons 5-9), PTEN (exons 5, 8), K-RAS (exon 1) genes were compared in epithelial and stromal components of 13 uterine carcinosarcomas. The tumours were classified as monoclonal in the presence of identical mutations in epithelial and stromal components, in the presence of different mutations - as biclonal. Of 13 cases 7 (53.8%) were monoclonal, 6 (46.2%) – biclonal.

Results

We evaluated clinical and histopathologic features of monoclonal and biclonal uterine carcinosarcomas. Monoclonal tumours showed worse prospects than the biclonal ones: 1-yr overall survival - 20% vs 37% (p = 0.0078). In all cases (100%) of monoclonal tumors the average length of full remission was three times shorter than in cases of biclonal tumours.Table: 15P

Comparison of monoclonal and biclonal carcinosarcomas

Clinical and morphological features of uterine carcinosarcomaMonoclonal tumoursBiclonal tumoursp ≦
Tumours invades the serosa of the corpus uteri, %100 %50 %p < 0.0001
Lymphovascular invasion80%0p < 0.0001
Average size of the tumour (cm3)1305.8131.5p < 0.05
Length of full remission7.7524.6p < 0.05

Conclusions

Clonality of the uterine carcinosarcomas may be a clinical marker as it determines the prospects of the disease, influencing the overall survival rate. Biclonal carcinosarcomas have a lesser potential for malignant development and are characterized by stronger survival capacity compared with the monoclonal tumours.

Clinical trial identification

Legal entity responsible for the study

Department of Oncology of the Russian Medical Academy of Continuous Vocational Training.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings